Today, 1.9 billion people are struggling with skin conditions such as acne, eczema and atopic dermatitis, according to the L’Oréal-owned dermatology brand
La Roche-Posay is reaching out to the 1.9 billion people around the world currently struggling with skin conditions with the launch of its first-ever TV brand campaign.
Going live in the UK and Ireland today, the L’Oréal-owned brand's #skinismorethanskin clip showcases real people with skin conditions such as acne, eczema and atopic dermatitis in a bid to raise awareness about how skin issues can impact consumers' mental health and alter the quality of their daily lives, while reassuring those who may be suffering that they are not alone.
According to the dermatology-based skin care brand's research carried out in partnership with non-proft organisation GlobalSkin, 79% of eczema patients have missed work due to their skin condition.
Meanwhile, 46% of those with acne were more likely to develop major depression and 50% of people with atopic dermatitis said that they felt stigmatised by society.
Laetitia Toupet, Global President at La Roche-Posay, said: “Whether big or small, skin issues are a matter of public health today.
“We tend to underestimate the impact they can have on people’s lives.
“That’s why at La Roche-Posay, we’ve always partnered with dermatologists and made science move forward to develop the best dermatological skin care solutions to change people’s lives.
“Today we’re going a step further with a brand new campaign to raise awareness and show the life-changing power of dermatology.”
The campaign comes as there has been a noted increase in skin issues during the Covid-19 pandemic, most notably 'maskne' as a result of consumers wearing face masks that can irritate the skin.
Speaking to Cosmetics Business last year, Gizela Lascelles, La Roche-Posay's UK Brand Business leader, revealed that online searches for '#acnetreatment' rose by 35%, while 45% of consumers are said to be spending more time on their skin care routine as a result of the Covid-19 lockdowns.
Read more in our exclusive interview with La Roche-Posay here.